Get the Stockscreener App
1.51
1.95%
-0.03
Aldeyra Therapeutics Inc stock is traded at $1.51, with a volume of 584.45K.
It is down -1.95% in the last 24 hours and down -68.54% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.54
Open:
$1.51
24h Volume:
584.45K
Relative Volume:
0.21
Market Cap:
$90.88M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-2.6783
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
-10.65%
1M Performance:
-68.54%
6M Performance:
-73.08%
1Y Performance:
-22.56%
1-Day Range:
$1.48
$1.56
1-Week Range:
$1.48
$1.87
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.51 | 92.68M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
425.82 | 110.47B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.98 | 80.67B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
751.82 | 46.53B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
315.01 | 43.81B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
159.95 | 35.36B | 606.42M | -1.28B | -997.58M | -6.403 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately - prnewswire.com
ALDX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aldeyra Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm - prnewswire.com
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud - GlobeNewswire
Allergic Conjunctivitis Clinical Trials Landscape 2026: Regulatory Approvals (FDA, EMA, PMDA), Drug Innovations, Mechanisms, Routes of Administration, IND/NDA Progress, and Companies | DelveInsight - Barchart
Aldeyra Therapeutics Faces Class Action Lawsuit Over Drug Trial Issues - National Today
ADLX Class Action Notice: Robbins LLP Reminds Investors of - GlobeNewswire
ADLX Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aldeyra Therapeutics, Inc. Class Action Lawsuit - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Norfolk Daily News
ALDX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
Shareholders who lost money in Aldeyra Therapeutics, Inc. - GlobeNewswire
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire
2026-04-03 | ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ALDX | Press Release - Stockhouse
ROSEN Attorneys Encourage Aldeyra Therapeutics Investors to Secure Counsel - National Today
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ADLX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Aldeyra Therapeutics, Inc. - Finansavisen
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) ... - Bluefield Daily Telegraph
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - Tullahoma News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming DeadlinesALDX - prnewswire.com
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ALDX SEC FilingsAldeyra Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BTIG Maintains ALDX (Aldeyra Therapeutics) at Buy on Mar 17, 2026 - Meyka
Aldeyra Therapeutics, Inc. 8-K SEC Filing April 2026 – Company Information, Address, and Trading Details - Minichart
ALDX Forecast, Price Target & Analyst Ratings | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
Aldeyra Therapeutics pays off $15 million outstanding borrowings, terminates Hercules credit facilitySEC filing - marketscreener.com
Aldeyra Therapeutics repays $15 million Hercules loan and ends credit facility By Investing.com - Investing.com South Africa
Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit FacilitySEC Filing - TradingView
Aldeyra Therapeutics repays $15 million Hercules loan and ends credit facility - Investing.com Canada
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility - TipRanks
Aldeyra pays off $15M loan, terminates Hercules credit facility - TradingView
Aldeyra (NASDAQ: ALDX) pays off $15M Hercules loan, extends runway - Stock Titan
Aldeyra Therapeutics, Inc. Pays Off $15 Million Outstanding Borrowings and Terminates Hercules Credit Facility - marketscreener.com
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The FirmALDX - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - natlawreview.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The FirmALDX - ACCESS Newswire
INVESTOR ALERT: Securities Class Action Filed Against Aldeyra Therapeutics – Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therap - GuruFocus
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ALDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - 巴士的報
Aldeyra (NASDAQ: ALDX) grants CEO 1.88M options and bonus units - Stock Titan
Aldeyra Therapeutics Sued for Securities Fraud - National Today
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):